Regeneron Pharmaceuticals Inc. — Sponsor Intelligence | 71 EU Trials

Filter these 71 trials by condition, phase, country and more.

Open in Search →

71 Registered trials

25 Recruiting

32 Completed trials

18 Countries active

72 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (FiH)

Phase III: 22 Phase II/III: 2 Phase II: 17 Phase I/II: 1 Phase IV: 1 Phase I: 15 Phase I (Other): 3 Phase I (FiH): 10

Oversight events:

1 serious breach 3 temporary halts 2 corrective measures across 4 trials

View oversight register →

100%

32 of 32 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 7 Malignant melanoma 3 Diffuse large B-cell lymphoma 3 Fallopian tube cancer 2 Ovarian cancer recurrent 2 Follicle centre lymphoma follicular grade I II III 2 Non-Hodgkin's lymphoma unspecified histology aggressive recurrent 2 Hereditary angioedema 2 Peritoneal cancer index 2 Food allergy 1 Lupus nephritis 1 Neoplasm malignant 1

Top IMPs

CEMIPLIMAB 16 LINVOSELTAMAB 7 DEXAMETHASONE 5 DIPHENHYDRAMINE HYDROCHLORIDE 5 FIANLIMAB 5 ODRONEXTAMAB 5 PARACETAMOL 5 CARBOPLATIN 4 CEMDISIRAN 4 CISPLATIN 4 DEXAMETHASONE SODIUM PHOSPHATE 4 DUPILUMAB 4

All trials — page 3

71 total

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended

2024-511653-22-00 Phase III 8 countries CEMIPLIMAB
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo… Ended

2024-511747-25-00 Phase II 5 countries ODRONEXTAMAB
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended

2023-509425-53-00 Phase III 3 countries DUPILUMAB
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas Halted

2022-502137-26-00 Phase I 3 countries
A Study of REGN7544 for the Treatment in Adult Patients with Sepsis-Induced Hypotension. Ended

2024-514946-35-00 Phase II 1 country REGN7544
Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Ended

2024-511440-76-00 Phase I 1 country
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults. Ended

2024-515285-14-00 Phase I 1 country
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally In… Ended

2023-508603-21-00 Phase II 3 countries HUMAN IGG4 S228P MONOCLONAL ANTIBODY AGAINST FACTOR XI AND ACTIVATED FACTOR XI; …
A trial to learn how well REGN7508 works for preventing blood clots after a knee replacement in adult participants Ended

2023-508602-14-00 Phase II 5 countries ENOXAPARIN SODIUM; REGN7508
A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies Ended

2023-508209-25-00 Phase I 3 countries
A trial to learn if different doses of REGN17092 are safe in healthy adults Ended

2023-505041-52-00 Phase I 1 country
A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended

2022-501470-18-00 Phase II 6 countries APIXABAN; ENOXAPARIN SODIUM; REGN9933
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants. Ended

2022-500398-15-00 Phase I 1 country REGN7999
REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy Ended

2023-508601-24-00 Phase I (FiH) 1 country REGN7257
Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies Ended

2022-500868-36-00 Phase I 1 country
Study of Cemiplimab in Patients with type of skin cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Ended

2022-500811-37-00 Phase II 1 country CEMIPLIMAB
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended

2024-510745-34-00 Phase II/III 4 countries DUPILUMAB
REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer Ended

2023-506248-18-00 Phase I (FiH) 1 country DAVUTAMIG
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended

2024-515051-38-00 Phase III 4 countries CARBOPLATIN; CEMIPLIMAB; CISPLATIN; IPILIMUMAB; PACLITAXEL; PEMETREXED
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Ended

2024-515052-20-00 Phase III 4 countries CARBOPLATIN; CEMIPLIMAB; CISPLATIN; GEMCITABINE; PACLITAXEL; PEMETREXED
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies Ended

2024-514938-20-00 Phase I 1 country
A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic… Ended

2023-507344-36-01 Phase II 1 country CEMIPLIMAB; VIDUTOLIMOD
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Aller… Ended

2024-511032-27-00 Phase I (Other) 1 country

Showing 49–71 of 71 trials

← All sponsors A–Z